First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Zymeworks Inc.

    ZYME · 2 developments mapped · last assessed 2026-09-10

    Market Ontology has mapped 2 macro, policy, and market developments to Zymeworks Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ZYME yet, so no modelled value is shown. The ZYME valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ZYME on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ZYME. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Main threat

      Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger

      Direct impact on merger completion probability and potential legal costs.

      · Moves probability of merger completion, synergy realization timeline, legal expenses

    • Open question

      Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR

      Direct acquisition of a public company, impacting financial structure, pipeline, and operational integration.

      · Moves future growth rates (pipeline expansion), synergy realization (cost savings, r&d efficiency), cost of capital (financing structure for acquisition)

    What changed, by assumption

    Probability of merger completion
    • 2026-09-10Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger
    Future growth rates (pipeline expansion)
    • 2026-08-21Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-06-29Cost of capitalBullishHigher cost-of-debt tranche lifts blended WACC.0.70
    2026-06-29Interest expenseBullishHigh-yield coupon materially raises interest burden.0.70
    2026-06-29Net debtBullishSub-IG debt raise increases leverage and net debt.0.70
    2026-06-29Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-06-29Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-06-29RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-10Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. mergerBearish1-3m0.70
    2026-08-21Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVRmixed3-12m0.70